US20130034601A1 - Method for increasing lactose tolerance in mammals exhibiting lactose intolerance - Google Patents
Method for increasing lactose tolerance in mammals exhibiting lactose intolerance Download PDFInfo
- Publication number
- US20130034601A1 US20130034601A1 US13/629,926 US201213629926A US2013034601A1 US 20130034601 A1 US20130034601 A1 US 20130034601A1 US 201213629926 A US201213629926 A US 201213629926A US 2013034601 A1 US2013034601 A1 US 2013034601A1
- Authority
- US
- United States
- Prior art keywords
- lactose
- pharmaceutical composition
- milk
- tbs
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Dairy Products (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Hematology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
The method for increasing lactose tolerance in subjects exhibiting lactose intolerance symptoms implements a protocol where the subjects ingest a gradually increasing amount of lactose containing product over a six week period. At various points during the six week period the subject ingests the lactose containing product once a day and then twice a day. The lactose containing product can be in liquid form, such as for example, milk, and is preferably in a powder form which is taken either by ingesting capsules having the lactose powder or in a granular form mixed with water or other non-lactose containing liquid. At the end of the six week period, the subject's tolerance for lactose containing products is substantially increased, with the potential of eliminating the subject's lactose intolerant behavior indefinitely.
Description
- This application claims priority from U.S. Provisional Patent Application Ser. No. 60/091,971 filed on Jul. 7, 1998.
- Lactose Intolerance, or otherwise referred to as lactose maldigestion, is the inability to digest a significant amount of lactose, derived from a deficiency of the lactase enzyme in the small intestines. Lactose is the natural sugar in milk and milk products of all mammals. Lactase is the enzyme which splits the milk sugar lactose into its components (i.e., glucose and galactose), and also breaks down the milk sugar into smaller forms that can be processed into the bloodstream. The lactase enzyme is necessary for mammals to digest lactose.
- There is an important distinction between lactose intolerance and milk allergies. Lactose intolerance is the inability of the body to digest lactose containing products due to a deficiency in the lactase enzyme. A milk allergy, however, is a sensitivity to the protein in milk, which involves the immune system and does not relate to a deficiency of the lactase enzyme. In humans, a milk allergy is usually experienced only by infants.
- Generally, humans develop lactose intolerance from a primary or secondary cause. The primary cause is an onset loss of lactase that is a permanent condition. This occurs at a variable period after the weaning period. The primary cause is also genetically determined. The secondary cause is generally a temporary condition that occurs as a result of another disease or event that damages the lining of the small intestine where lactase is active. This is usually caused by an acute diarrheal disease, parasitic infection, Crohn's disease, celiac disease, gastrointestinal surgery, or the intake of certain medications.
- In addition to the primary and secondary causes, certain human ethnic and racial populations have more of a predisposition for lactose intolerance. In these populations, social and cultural habits and attitudes influence lactose intolerance. Lactose activity can also decrease with age in certain ethnic and racial populations, including those populations which have origins in Europe, the African plains, and the Siberian Steppes, Humans who are most likely to have or develop lactose intolerance include those of Asian, Middle Eastern, North American, African, and Latin American descent.
- According to several sources, there are 30 to 50 million people in the world who are lactose intolerant, in the 1960's and 1970's, it was reported that 70% of the adults in the world had lactose intolerance. In 1995, is was reported that 75% of the adults in the world and 25% of the adults in the U.S. were categorized as being lactose intolerant. In 1994, it was reported that 75% of African Americans and Native Americans and 90% of Asian Americans had lactose intolerance. It has also been reported that 30% of adults who are mostly North Western and North American descendants of the Europeans, have adapted to high lactase activity into adulthood. Research concludes that this adaptation is genetically controlled, permanent and related, to a long tradition of milk and milk products consumption in these regions of the world.
- Lactose intolerance can be tested either indirectly or directly. There are three main ways to test by the indirect method: a hydrogen breath test, a stool acidity test, or a blood glucose test. In the hydrogen breath test, the breath is measured to determine the amount of hydrogen produced after consuming a measured amount of lactose, typically 15 g. The lactose is consumed by drinking a lactose mixture, and the subject exhales into a vacuum-sealed collection tube at three one hour time intervals. A high level of hydrogen in the breath indicates an improper digestion of lactose. In a stool test, the stool is tested to determine the amount of acid. In a blood glucose test, the blood is tested to determine the amount of glucose (sugar) content after administering a predetermined amount of lactose-containing product to the subject. The direct method measures lactose activity in a mucosal biopsy specimen.
- If an individual suspects that he has lactose intolerance, it is potentially harmful for him to restrict his diet since it may result in a nutrition shortage or a failure to detect a more serious disease. Milk and other dairy products are major sources for nutrition in the basic American diet. The primary nutrients in milk are protein, calcium, riboflavin, vitamin A, and vitamin D. Calcium is an important part of the recommended daily allowances of vitamins and minerals and any deficiency therein can lead to osteoporosis.
- When an individual has an allergic reaction to milk, there are several different resulting symptoms depending on the age of the individual. For young adults and adults, symptoms include bloating, nausea, cramps, and diarrhea, while the symptoms in infants are diarrhea, dehydration, malnutrition, and potentially death. Some of the symptoms vary based on the level of tolerance the person has, the amount and type of lactose consumed, or the remainder of the person's diet.
- Lactose is not digested when the amount of lactose consumed exceeds the lactase enzyme capacity of the small intestine. Instead, excess undigested lactose passes through the small intestines into the large intestine where it is fermented by a bacteria called colinic flora. The fermentation of the lactose in the large intestine produces hydrogen and methane which can lead to bloating, gas, and diarrhea. These symptoms are caused by a very low activity of lactase in the intestines.
- The use of lactase tablets which are generally available, help lactose intolerant people digest milk and milk products. Each lactase tablet typically hydrolyzes up to 99% of the ingested lactose within 24 hours, and is designed to be ingested with the lactose containing food.
- Young children who have lactose intolerance are very rare. The amount of lactase enzyme a body produces generally reaches a maximum immediately after birth and then decreases in the majority of people after their body adjusts during the ages of 3-15. A stool test is used to test lactose intolerance in young children. For young children, the breath test is not as accurate because they usually have a tendency to get dehydrated which can cause diarrhea.
- The reasons for an onset of lactose intolerance are generally unknown. However, there is a general belief that by consuming small amounts of lactose frequently over a period of time, lactose intolerance can be improved. Whole milk and chocolate milk appear to be tolerated better than low fat milk because the fat content of whole milk and chocolate milk slows the rate of gastric emptying. Many lactose intolerant people can have at least 8 oz of milk. Also, many lactose intolerant people can have hard cheeses because during manufacturing most of the lactose is removed with the whey. During the aging of the cheeses, the remaining lactose is converted to lactic acid and other products. As a result, most aged cheeses have little to no lactose. Some of such firm cheeses include cheddar, Swiss and mozzarella. Another product that lactose intolerant people can tolerate is yogurt, with live culture bacteria in it. Having yogurt with a non-fermented dairy product can improve lactose digestion.
- People typically have different symptoms of lactose intolerance. Lactose intolerance may also be psychologically induced. There are also many different variations of lactose intolerance depending on the individual. For example, some individuals cannot have cheese, melted cheese, plain milk, or warm dairy containing products like milk in coffee, while others cannot have any dairy products at all. Also, most lactose intolerant people are limited as to the amount of special “lactose free” foods they can eat that have been manufactured by specific companies. Some examples of these “lactose free” foods are: Mocha Mix ice cream, Tofutti ice cream and ice cream sandwiches, LACTAID® brand milk, Formagg cheese, Tofutti “Better than Cream Cheese”, margarine, and live cultured yogurt. The only problem with all these products is that they are not readily available everywhere.
- The present invention provides a method for increasing the lactose tolerance of mammals exhibiting lactose intolerance symptoms. In accordance with the invention, a six-week protocol is employed during which a subject ingests gradually increasing amounts of a lactose-containing product. On the first and second days of the protocol, the subject also ingests a predetermined amount of a live culture bacteria containing compound, such as yogurt. Toward the end of the six-week period, the subject starts ingesting other lactose-containing products while continuing to ingest the predetermined amount of lactose containing product. By the conclusion of the six-week protocol, the subject's tolerance for lactose-containing products is significantly increased, and in some cases, the subject no longer experiences any lactose intolerance or the symptoms associated therewith.
- In accordance with a preferred embodiment of the invention, the lactose- containing product is administered to the subject is in the form of a lactose powder. The lactose powder can be provided within an ingestable capsule or in granular form which is measured out and added to the subject meal or drink.
- The various features of novelty which characterize the invention are pointed out with particularity in the claims annexed to and forming a part of the disclosure.
- According to a first embodiment of the invention, a predetermined fist dose of a liquid form of a lactose-containing product, such as, for example milk, is administered to the subject once each day in gradually increasing amounts during the course of a six-week period. On the first and second days, a predetermined amount of a substance containing live cultured bacteria, such as yogurt, is administered to the subject with the dose of lactose-containing product. Subsequently, during the six-week period, a second dose of the liquid form of lactose, in addition to the first dose, is administered to the subject at a second time during each day.
- An example of this dosing regimen is shown below in Table 1. On the first day, the subject ingests 8 ounces of live culture bacteria yogurt with 1 tablespoon of milk with dinner. On day 2, the amount of yogurt ingested is reduced to 4 ounces and the amount of milk administered remains the same. On day 3, administration of the yogurt is ceased, and the milk dose remains at one tablespoon. During days 4 through 18, the amount of milk ingested with dinner is increased by one tablespoon each day until 16 tablespoons are reached on day 18. On day 19, a second dose, 1 tablespoon, of milk is ingested in the morning with breakfast and 16 tablespoons of milk are ingested with dinner. From day 16 until day 34, the subject continues to ingest 16 tablespoons of milk with dinner. The morning dose is increased daily at a rate of 1 tablespoon per day so that by day 34 the subject ingests 16 tablespoons of milk with breakfast and 16 tablespoons with dinner. On day 35, the subject discontinues ingesting the lactose containing product in tablespoon doses and begins ingesting milk, starting with 9 ounces in the morning and 9 ounces in the evening with the meals. The amount of milk is increased an ounce each day so that by day 38, the subject ingests 12 ounces of milk with both breakfast and dinner.
- On day 39, the subject discontinues the milk intake and instead ingests 1 ounce of cheese. The amount of cheese is increased to 2 ounces on day 40. By day 41, the subject's lactose intolerance has been completely eliminated, and the subject is free to eat any dairy product of his choice.
-
TABLE 1 Week Day PM-Dosage AM-Dosage 1 1 1 tbs + 8 oz yogurt 1 2 1 tbs + 4 oz yogurt 1 3 1 tbs 1 4 2 tbs 1 5 3 tbs 1 6 4 tbs 1 7 5 tbs 2 8 6 tbs 2 9 7 tbs 2 10 8 tbs 2 11 9 tbs 2 12 10 tbs 2 13 11 tbs 2 14 12 tbs 3 15 13 tbs 3 16 14 tbs 3 17 15 tbs 3 18 16 tbs 3 19 16 tbs 1 tbs 3 20 16 tbs 2 tbs 3 21 16 tbs 3 tbs 4 22 16 tbs 4 tbs 4 23 16 tbs 5 tbs 4 24 16 tbs 6 tbs 4 25 16 tbs 7 tbs 4 26 16 tbs 8 tbs 4 27 16 tbs 9 tbs 4 28 16 tbs 10 tbs 5 29 16 tbs 11 tbs 5 30 16 tbs 12 tbs 5 31 16 tbs 13 tbs 5 32 16 tbs 14 tbs 5 33 16 tbs 15 tbs 5 34 16 tbs 16 tbs 5 35 9 oz milk 9 oz milk 6 36 10 oz milk 10 oz milk 6 37 11 oz milk 11 oz milk 6 38 12 oz milk 12 oz milk 6 39 Cheese 1 oz 6 40 Cheese 2 oz 6 41 lactose tolerance achieved 6 42 - Table 1 shows an exemplary six-week protocol however, the actual days on which the doses are changed and the quantity of the doses can be modified according to the subject and his specific reactions without departing from the scope of the invention. For example, the subject may be capable of ingesting more than 5 tablespoons of milk by day 7, and could therefore increase it to 6 tablespoons on day 7, and so on. Alternatively, the subject may find that the transition from 5 tablespoons on day 7 (which he is capable of ingesting without any adverse effect) to 6 tablespoons on day 8 may result in an adverse effect. As such, the subject may revert back to the 5 tablespoon dose and continue that dose for a longer period than originally prescribed (e.g., 2 or more days) before increasing the dosage again. The same variable modification to the protocol applies to the lactose powder protocol described below with reference to Table 2.
- In another embodiment of the present invention, the lactose containing product administered to the subject is a pure powder lactose that is contained in an ingestable capsule or an equivalent amount in a loose granular form mixed with water or other non-lactose containing product. An example of the powder lactose regimen is shown in Table 2, In Table 2, the designation “s” refers to a 1 zero sized capsule filled with 0.8 grams of pure powder lactose (which is equivalent to 1 tablespoon of milk), and “m” refers to a double sized zero capsule filled with 1.6 grams of pure lactose powder. The amount of lactose ingested in any period in accordance with the regimen shown in Table 2 is identical to that of the regimen shown in Table 1 except that the form of the lactose is different.
-
TABLE 2 Week Day PM-Dosage AM-Dosage 1 1 s + 8 oz yogurt 1 2 s + 4 oz yogurt 1 3 s 1 4 m 1 5 m + s 1 6 2m 1 7 2m + s 2 8 3m 2 9 3m + s 2 10 4m 2 11 4m + s 2 12 5m 2 13 5m + s 2 14 6m 3 15 6m + s 3 16 7m 3 17 7m + s 3 18 8m 3 19 8m s 3 20 8m m 3 21 8m m + s 4 22 8m 2m 4 23 8m 2m + s 4 24 8m 3m 4 25 8m 3m + s 4 26 8m 4m 4 27 8m 4m + s 4 28 8m 5m 5 29 8m 5m + s 5 30 8m 6m 5 31 8m 6m + s 5 32 8m 7m 5 33 8m 7m + s 5 34 8m 8m 5 35 9 oz milk 9 oz milk 6 36 10 oz milk 10 oz milk 6 37 11 oz milk 11 oz milk 6 38 12 oz milk 12 oz milk 6 39 Cheese 1 oz 6 40 Cheese 2 oz 6 41 lactose tolerance achieved 6 42 - The method of the present invention was initially tested on the applicant and after obtaining positive results, additional testing was performed on 10 adult human subjects. Five of the subjects followed the liquid protocol of Table 1, while the other five followed the capsule protocol of Table 2. Some of the test subjects experienced mild gas and discomfort at various points early in the program. At the end of the protocol; eight of the ten subjects tested considered themselves “cured” of lactose intolerance. One of the two who did not achieve the desired results interrupted the protocol by stopping in the middle and subsequently tried to restart a week later. This subject attributed his failure to stopping in the middle and to ingesting other foods such as creamed spinach, pizza, frozen yogurt, chocolate and other lactose containing foods during the protocol period. The other did not finish the six week protocol. The subjects who strictly followed the six-week protocol program for increasing lactose tolerance increased their lactose tolerance to a point where they are free to enjoy any lactose containing food of their choice.
- Although the doses shown here have been used and tested, variations in the doses and timing in which they are administered can still result in an effective treatment for increasing tolerance for lactose containing products. For example, the presented doses have been tested on adult subjects. Thus, when applying the protocol of the present invention to younger subjects, the weight of the subject might be a consideration. For example, a subject weighing 50 pounds may not require, and may not be capable of tolerating, the doses set forth in Tables 1 and 2 at the prescribed time in the protocol. As such, the dose administered to the subject may be proportionally scaled down based on his weight. Although the two doses are disclosed as being administered with breakfast and dinner, alternatively the order of the doses maybe switched, or may be administered at other times of the day with meals such as lunch or snacks (or conceivably with no meals). Although the invention has been described for use in humans, it is also capable of being administered to other mammals.
- The invention is not limited by the embodiments described above which are presented as examples only but can be modified in various ways within the scope of protection defined by the appended patent claims.
Claims (21)
1-24. (canceled)
25. An orally administered pharmaceutical composition for the treatment of lactose intolerance comprising a lactose powder and bacteria, wherein a single dose of the pharmaceutical composition comprises from about 0.8 g to about 12.8 g of the lactose powder.
26. The orally administered pharmaceutical composition of claim 25 , wherein the bacteria are live cultured bacteria.
27. The orally administered pharmaceutical composition of claim 25 , wherein the single dose of the pharmaceutical composition is provided in one or more ingestible capsules.
28. The orally administered pharmaceutical composition of claim 27 , wherein at least one of the one or more ingestible capsules comprises about 0.8 g of the lactose powder.
29. The orally administered pharmaceutical composition of claim 27 , wherein at least one of the one or more ingestible capsules comprises about 1.6 g of the lactose powder.
30. The orally administered pharmaceutical composition of claim 27 , wherein at least one of the one or more ingestible capsules is a zero sized capsule.
31. The orally administered pharmaceutical composition of claim 27 , wherein at least one of the one or more ingestible capsules is a double zero sized capsule.
32. The orally administered pharmaceutical composition of claim 25 , wherein the pharmaceutical composition is configured for administration to a mammal.
33. The orally administered pharmaceutical composition of claim 25 , wherein the pharmaceutical composition is configured for administration to a human.
34. A composition consisting essentially of a lactose powder in an ingestible capsule.
35. The composition of claim 34 , wherein the ingestible capsule comprises about 0.8 g of the lactose powder.
36. The composition of claim 34 , wherein the ingestible capsule comprises about 1.6 g of the lactose powder.
37. The composition of claim 34 , wherein the ingestible capsule is a size zero capsule.
38. The composition of claim 34 , wherein the ingestible capsule is a size double zero capsule.
39. A method for treating lactose intolerance in a subject who has experienced symptoms of lactose intolerance, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a lactose powder.
40. The method of claim 39 , wherein the pharmaceutical composition further comprises bacteria.
41. The method of claim 39 , wherein the effective amount of the pharmaceutical composition comprises from about 0.8 g to about 12.8 g of the lactose powder.
42. The method of claim 39 , wherein the pharmaceutical composition is provided in one or more ingestible capsules.
43. The method of claim 42 , wherein at least one of the ingestible capsules is a size zero capsule.
44. The method of claim 42 , wherein at least one of the ingestible capsules is a size double zero capsule.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/629,926 US20130034601A1 (en) | 1998-07-07 | 2012-09-28 | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
US14/062,530 US20140234407A1 (en) | 1998-07-07 | 2013-10-24 | Method for Increasing Lactose Tolerance in Mammals Exhibiting Lactose Intolerance |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9197198P | 1998-07-07 | 1998-07-07 | |
US09/346,479 US7029702B2 (en) | 1998-07-07 | 1999-07-01 | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
US11/330,369 US20060104965A1 (en) | 1998-07-07 | 2006-01-10 | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
US12/013,161 US7879363B2 (en) | 1998-07-07 | 2008-01-11 | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
US12/973,501 US20110086093A1 (en) | 1998-07-07 | 2010-12-20 | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
US13/629,926 US20130034601A1 (en) | 1998-07-07 | 2012-09-28 | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/973,501 Continuation US20110086093A1 (en) | 1998-07-07 | 2010-12-20 | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/062,530 Continuation US20140234407A1 (en) | 1998-07-07 | 2013-10-24 | Method for Increasing Lactose Tolerance in Mammals Exhibiting Lactose Intolerance |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130034601A1 true US20130034601A1 (en) | 2013-02-07 |
Family
ID=26784526
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/346,479 Expired - Fee Related US7029702B2 (en) | 1998-07-07 | 1999-07-01 | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
US11/330,369 Abandoned US20060104965A1 (en) | 1998-07-07 | 2006-01-10 | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
US12/013,161 Expired - Fee Related US7879363B2 (en) | 1998-07-07 | 2008-01-11 | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
US12/973,501 Abandoned US20110086093A1 (en) | 1998-07-07 | 2010-12-20 | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
US13/629,926 Abandoned US20130034601A1 (en) | 1998-07-07 | 2012-09-28 | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
US14/062,530 Abandoned US20140234407A1 (en) | 1998-07-07 | 2013-10-24 | Method for Increasing Lactose Tolerance in Mammals Exhibiting Lactose Intolerance |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/346,479 Expired - Fee Related US7029702B2 (en) | 1998-07-07 | 1999-07-01 | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
US11/330,369 Abandoned US20060104965A1 (en) | 1998-07-07 | 2006-01-10 | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
US12/013,161 Expired - Fee Related US7879363B2 (en) | 1998-07-07 | 2008-01-11 | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
US12/973,501 Abandoned US20110086093A1 (en) | 1998-07-07 | 2010-12-20 | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/062,530 Abandoned US20140234407A1 (en) | 1998-07-07 | 2013-10-24 | Method for Increasing Lactose Tolerance in Mammals Exhibiting Lactose Intolerance |
Country Status (1)
Country | Link |
---|---|
US (6) | US7029702B2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080126195A1 (en) * | 2004-07-22 | 2008-05-29 | Ritter Andrew J | Methods and Compositions for Treating Lactose Intolerance |
US8785160B2 (en) | 2009-02-24 | 2014-07-22 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
US9579340B2 (en) | 2009-02-24 | 2017-02-28 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
US20180144743A1 (en) * | 2016-11-21 | 2018-05-24 | Google Inc. | Providing prompt in an automated dialog session based on selected content of prior automated dialog session |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7029702B2 (en) * | 1998-07-07 | 2006-04-18 | Ritter Natural Sciences Llc | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
US20090117184A1 (en) * | 2007-11-05 | 2009-05-07 | Sabine Fricke | Use of a gestagen in combination with an estrogen and one or more pharmaceutically acceptable auxiliary agents/excipients for lactose-free oral contraception |
US20110223248A1 (en) * | 2007-12-12 | 2011-09-15 | Ritter Pharmaceuticals, Inc. | Methods and compositions for treating lactose intolerance |
WO2010008491A2 (en) * | 2008-06-25 | 2010-01-21 | Ritter Natural Sciences, Llc | Lactose compositions with decreased lactose content |
US20150087616A1 (en) * | 2011-11-30 | 2015-03-26 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
CN114832092A (en) * | 2013-07-12 | 2022-08-02 | 艾尔牛奶有限公司 | Beta-casein A2 and reducing or preventing symptoms of lactose intolerance |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3627583A (en) | 1969-04-29 | 1971-12-14 | Sucrest Corp | Direct compression vehicles |
JPS6078540A (en) | 1983-10-05 | 1985-05-04 | Kansai Runa Kk | Production of fermented milk containing carbon dioxide gas, alcohol, etc. |
JPS60221078A (en) * | 1984-04-18 | 1985-11-05 | Morinaga Milk Ind Co Ltd | Granular product of useful microorganism powder and its preparation |
JPS6163618A (en) * | 1984-09-03 | 1986-04-01 | Akira Yamauchi | Cathartic |
US4839281A (en) | 1985-04-17 | 1989-06-13 | New England Medical Center Hospitals, Inc. | Lactobacillus strains and methods of selection |
CA1308661C (en) * | 1987-06-26 | 1992-10-13 | Masayasu Kurono | AGENT FOR INHIBITING BINDING OF 5.alpha.-DIHYDRO-TESTOSTERONE WITH ANDROGEN RECEPTOR AS WELL AS PROCESS FOR OBTAINING SAME |
US4806368A (en) * | 1987-09-16 | 1989-02-21 | Reddy Malireddy S | Shelf life and subsequent growth of lactobacillus acidophilus, propionibacterium shermanii and leuconostoc citrovorum in dietary fiber based supplement preparation |
US4959234A (en) * | 1988-11-17 | 1990-09-25 | Electric Power Research Institute | Method for improving the taste, texture and mouth feel of a liquid dairy product and for concentrating same |
US5219842A (en) | 1989-08-29 | 1993-06-15 | Nihon Shokuhin Kako Co., Ltd. | Method of improving intestinal floras |
FI88856C (en) | 1990-05-18 | 1997-07-01 | Alko Yhtioet Oy | Foerfarande Foer framstaellning av ett fermenterat, huvudsakligen pao havrekli baserat, levande mikroorganismer innehaollande livsmedel |
DE69108146T2 (en) | 1990-09-05 | 1995-09-28 | Terumo Corp | Insoluble dietary FIBERS, process for their preparation and foods containing dietary FIBERS. |
CA2056167A1 (en) * | 1991-11-25 | 1993-05-26 | James Joseph Miller | Body dusting powder containing live bacterial culture |
US5716615A (en) * | 1992-02-10 | 1998-02-10 | Renata Maria Anna Cavaliere Vesely | Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use |
US5550106A (en) * | 1994-03-04 | 1996-08-27 | Bristol-Myers Squibb Company | Low buffer nutritional composition |
WO1995033046A1 (en) | 1994-05-26 | 1995-12-07 | Bracco S.P.A. | Lactobacillus strains of human origin, their compositions and uses thereof |
IT1270216B (en) * | 1994-06-14 | 1997-04-29 | Recordati Chem Pharm | METHOD OF STABILIZATION OF BIOLOGICALLY ACTIVE COMPOUNDS BY MICROGRANULES COVERED SUSPENDABLE IN FOOD FLUIDS |
US6241983B1 (en) | 1994-10-28 | 2001-06-05 | Metagenics, Inc. | Bacteria-and fiber-containing composition for human gastrointestinal health |
US5531989A (en) | 1994-10-28 | 1996-07-02 | Metagenics, Inc. | Immunoglobulin and fiber-containing composition for human gastrointestinal health |
AUPN881396A0 (en) | 1996-03-20 | 1996-04-18 | Arnott's Biscuits Limited | Enhancement of microbial colonization of the gastrointestinal tract |
ATE169456T1 (en) | 1996-12-23 | 1998-08-15 | Sitia Yomo Spa | LYOPHILIZED FOOD COMPOSITION CONTAINING LIVE BAKERIA |
DE19736047A1 (en) * | 1997-08-20 | 1999-02-25 | Voith Sulzer Papiermasch Gmbh | Device and method for controlling or regulating the basis weight of a paper or cardboard web |
US6093425A (en) | 1997-11-21 | 2000-07-25 | Princeton Nutrition, L.L.C. | Complete nutritional milk compositions and products |
US5952205A (en) | 1998-02-06 | 1999-09-14 | Neose Technologies, Inc. | Process for processing sucrose into glucose and fructose |
AU759465B2 (en) | 1998-05-05 | 2003-04-17 | Mcneil Specialty Products Company Division Of Mcneil-Ppc, Inc. | Functional sugar polymers from inexpensive sugar sources and apparatus for preparing same |
US7029702B2 (en) * | 1998-07-07 | 2006-04-18 | Ritter Natural Sciences Llc | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
US7767203B2 (en) | 1998-08-07 | 2010-08-03 | Ganeden Biotech, Inc. | Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption |
PT1112002E (en) | 1998-09-08 | 2002-11-29 | Nestle Sa | MILK IN POINT FOR ANIMAL FEEDING |
ID29150A (en) | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | USE OF LACTOBACILLUS SALIVARIUS |
EP1034787A1 (en) | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactobacillus strains preventing diarrhea caused by pathogenic bacteria |
WO2000061155A1 (en) | 1999-04-08 | 2000-10-19 | Khan Airudin S | Composition, containing sublimed sulfur, for the treatment of lactose intolerance |
US20040161422A1 (en) | 1999-04-30 | 2004-08-19 | Natarajan Ranganathan | Nutritional compositions comprising probiotics |
US6706287B2 (en) | 2001-05-15 | 2004-03-16 | Kibow Biotech Inc. | Prebiotic and probiotic compositions and methods for their use in gut-based therapies |
US6468525B1 (en) | 1999-08-10 | 2002-10-22 | Renew Life, Inc. | Probiotic formulation |
CA2400969C (en) | 2000-03-01 | 2011-04-19 | Societe Des Produits Nestle S.A. | Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response to measles vaccine |
GB2369777B (en) | 2000-10-05 | 2004-10-27 | St Ivel Ltd | Food products with antimicrobial lactic acid bacteria |
GB0027761D0 (en) | 2000-11-14 | 2000-12-27 | Nestle Sa | Nutritional composition for an immune condition |
CA2442602A1 (en) | 2000-12-18 | 2002-08-01 | Probio Health, Llc | Probiotic compounds derived from lactobacillus casei strain ke01 |
JP3921175B2 (en) | 2001-04-02 | 2007-05-30 | わかもと製薬株式会社 | Composition for prevention and / or treatment of oral disease |
US20030017192A1 (en) | 2001-06-19 | 2003-01-23 | Hanny Kanafani | Process for producing extended shelf-life ready-to-use milk compositions containing probiotics |
EP1429620A1 (en) | 2001-08-31 | 2004-06-23 | Nutricopia, Inc. | Nutritional frozen dessert and methods of menufacture |
GB2382528B (en) | 2001-11-12 | 2004-05-05 | Mars Inc | A consumable composition for the development of a healthy gastrointestinal tract |
KR20030064030A (en) | 2002-01-25 | 2003-07-31 | 주식회사 푸코 | Novel probiotic strain isolated from Korean feces having gastric juice-resistance, bile acid-resistance and its use |
US7101565B2 (en) | 2002-02-05 | 2006-09-05 | Corpak Medsystems, Inc. | Probiotic/prebiotic composition and delivery method |
DE20202562U1 (en) | 2002-02-19 | 2002-05-23 | Orthomol Pharmazeutische Vertr | Micronutrient combination product with probiotics and prebiotics |
US20050074442A1 (en) | 2002-03-13 | 2005-04-07 | Natarajan Ranganathan | Compositions and methods for augmenting kidney function |
SE0201214D0 (en) | 2002-04-23 | 2002-04-23 | Jafar Mahdavi | Multicultural fermented yogurt |
DK1565547T4 (en) * | 2002-06-28 | 2013-01-14 | Biosearch S A | Probiotic strains, a method of selection thereof, preparations thereof, and use thereof |
ITBO20020564A1 (en) | 2002-09-06 | 2004-03-07 | Alfa Wassermann Spa | BIFIDOBACTERIA AND PREPARATIONS THAT CONTAIN THEM. |
WO2004037191A2 (en) | 2002-10-22 | 2004-05-06 | University Of Vermont And State Agriculture College | Symbiotic food products comprising oats and methods for manufacturing the same |
ATE513551T1 (en) | 2003-01-24 | 2011-07-15 | Flora Technology Inc | COMPOSITIONS AND METHODS FOR RESTORING BACTERIAL FLORA |
WO2004069156A2 (en) * | 2003-01-30 | 2004-08-19 | The Regents Of The University Of California | Inactivated probiotic bacteria and methods of use thereof |
GB0308104D0 (en) | 2003-04-08 | 2003-05-14 | Novartis Nutrition Ag | Organic compounds |
FI20030610A0 (en) | 2003-04-22 | 2003-04-22 | Raisio Benecol Oy | Edible product |
US20040265279A1 (en) | 2003-05-08 | 2004-12-30 | Timothy Dinan | Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity |
ATE306821T1 (en) | 2003-09-18 | 2005-11-15 | Pm Int Ag | POWDER TO MAKE A PROBIOTIC YOGURT DISH |
JP2005110112A (en) * | 2003-10-01 | 2005-04-21 | Nec Corp | Method for authenticating radio communication device in communication system, radio communication device, base station and authentication device |
US20080126195A1 (en) | 2004-07-22 | 2008-05-29 | Ritter Andrew J | Methods and Compositions for Treating Lactose Intolerance |
US20060093592A1 (en) | 2004-10-04 | 2006-05-04 | Nutracea | Synbiotics |
AU2006214382C1 (en) | 2005-02-15 | 2012-03-08 | Barry R. Goldin | A food containing a probiotic and an isolated beta-glucan and methods of use thereof |
US20060240148A1 (en) | 2005-04-13 | 2006-10-26 | The Dannon Company, Inc. | High-fiber dairy product |
DE202005009120U1 (en) | 2005-06-10 | 2005-11-10 | Peterik, Josef | Bifidoactive probiotic yogurt, useful to promote human health, comprises skimmed milk, milk powder, starch, milk proteins and bacterial cultures of e.g. Streptococcus salivarius subsp. thermophilus and Bifidobacterium |
AT501919B1 (en) | 2005-06-14 | 2008-09-15 | Erber Ag | PROBIOTIC, HEALTH OR BZW. PERFORMANCE-ADDING FEED AND / OR DRINKING WATER SUPPLEMENT FOR ANIMALS AND ITS USE |
FR2889958A1 (en) | 2005-08-25 | 2007-03-02 | Lyoct Sa Lab | USE OF A SYMBIOTIC FOR THE TREATMENT OF ATOPIC DERMATITIS |
WO2007095425A1 (en) | 2006-02-13 | 2007-08-23 | Mcneil Nutritionals, Llc | Lactose-reduced dairy compositions and related methods |
EP2012596A1 (en) | 2006-05-03 | 2009-01-14 | Anidral S.R.L. | Symbiotic composition comprising non-digestible polysaccharides and bifidobacteria which metabolize them and its uses |
US20080254166A1 (en) | 2007-01-25 | 2008-10-16 | Potter Susan M | Food Additives Containing Combinations of Prebiotics and Probiotics |
US20110223248A1 (en) * | 2007-12-12 | 2011-09-15 | Ritter Pharmaceuticals, Inc. | Methods and compositions for treating lactose intolerance |
WO2010008491A2 (en) * | 2008-06-25 | 2010-01-21 | Ritter Natural Sciences, Llc | Lactose compositions with decreased lactose content |
-
1999
- 1999-07-01 US US09/346,479 patent/US7029702B2/en not_active Expired - Fee Related
-
2006
- 2006-01-10 US US11/330,369 patent/US20060104965A1/en not_active Abandoned
-
2008
- 2008-01-11 US US12/013,161 patent/US7879363B2/en not_active Expired - Fee Related
-
2010
- 2010-12-20 US US12/973,501 patent/US20110086093A1/en not_active Abandoned
-
2012
- 2012-09-28 US US13/629,926 patent/US20130034601A1/en not_active Abandoned
-
2013
- 2013-10-24 US US14/062,530 patent/US20140234407A1/en not_active Abandoned
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080126195A1 (en) * | 2004-07-22 | 2008-05-29 | Ritter Andrew J | Methods and Compositions for Treating Lactose Intolerance |
US9226933B2 (en) | 2004-07-22 | 2016-01-05 | Ritter Pharmaceuticals, Inc. | Methods and compositions for treating lactose intolerance |
US8785160B2 (en) | 2009-02-24 | 2014-07-22 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
US9579340B2 (en) | 2009-02-24 | 2017-02-28 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
US9592248B2 (en) | 2009-02-24 | 2017-03-14 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
US9775860B2 (en) | 2009-02-24 | 2017-10-03 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
US9808481B2 (en) | 2009-02-24 | 2017-11-07 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
US20180144743A1 (en) * | 2016-11-21 | 2018-05-24 | Google Inc. | Providing prompt in an automated dialog session based on selected content of prior automated dialog session |
Also Published As
Publication number | Publication date |
---|---|
US7029702B2 (en) | 2006-04-18 |
US7879363B2 (en) | 2011-02-01 |
US20060104965A1 (en) | 2006-05-18 |
US20080112941A1 (en) | 2008-05-15 |
US20140234407A1 (en) | 2014-08-21 |
US20020034496A1 (en) | 2002-03-21 |
US20110086093A1 (en) | 2011-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7879363B2 (en) | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance | |
McBEAN et al. | Allaying fears and fallacies about lactose intolerance | |
Savaiano et al. | Milk intolerance and microbe-containing dairy foods | |
Montalto et al. | Management and treatment of lactose malabsorption | |
RU2763172C2 (en) | Use of lactic acid bacteria for treatment or prevention of at least one condition of postnatal depression and postnatal anxiety | |
MXPA99001203A (en) | Anti-stress drugs and functional foods having anti-stress effects. | |
US9226933B2 (en) | Methods and compositions for treating lactose intolerance | |
Colman et al. | Prevention of folate deficiency by food fortification. III. Effect in pregnant subjects of varying amounts of added folic acid | |
Srinivasan et al. | When to suspect lactose intolerance: symptomatic, ethnic, and laboratory clues | |
US20220387527A1 (en) | Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus | |
Morelli et al. | Lactose intolerance: clinical symptoms, diagnosis and treatment | |
Gomes et al. | Effect of increased calcium consumption from fat-free milk in an energy-restricted diet on the metabolic syndrome and cardiometabolic outcomes in adults with type 2 diabetes mellitus: a randomised cross-over clinical trial | |
Varela-Moreiras et al. | Effects of yogurt and fermented-then-pasteurized milk on lactose absorption in an institutionalized elderly group | |
Solomons et al. | The effect of dietary lactose on the early recovery from protein-energy malnutrition. I. Clinical and anthropometric indices | |
Gomes et al. | High calcium intake from fat-free milk, body composition and glycaemic control in adults with type 2 diabetes: a randomised crossover clinical trial | |
Gaskin et al. | Lactose maldigestion revisited: Diagnosis, prevalence in ethnic minorities, and dietary recommendations to overcome it | |
Rosado et al. | Lactose Digestion and Clinical Tolerance to Milk, Lactose‐Prehydrolyzed Milk and Enzyme‐Added Milk: A Study in Undernourished Continuously Enteral‐Fed Patients | |
Alshanbari et al. | Caffeine effect on bone mineral density: A cross-sectional study | |
CN100579606C (en) | Use of whey permeate for the treatment of metabolic syndrome | |
Amschler | Calcium intake: a lifelong proposition | |
Gerbault et al. | Lactose malabsorption and nutrition | |
Elmacioglu et al. | Is adequate and balanced nutrition during pregnancy more effective than iron and folic acid supplements? | |
Bakhsh | Lactose Intolerance | |
EP4136985A1 (en) | Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus | |
Brand | Lactose malabsorption and its relation to human growth and nutrition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: RITTER PHARMACEUTICALS, INC., CALIFORNIA Free format text: ASSIGNEE CHNAGE OF ADDRESS;ASSIGNOR:RITTER PHARMACEUTICALS, INC.;REEL/FRAME:037273/0837 Effective date: 20151104 |